We lead the way.
You see the results.
Innovations inspired by the needs of your eyes
Every eye is different. ACUVUE is inspired by them all. Our EYE-INSPIRED Innovations tap into the science of the eye to deliver exceptional vision experiences.#
Here for you, every step of the way
Footnotes
^JJV Data on File 2023. Data Substantiation for ACUVUE Claims Globally_DEC2023
§Survey among 1,002 Eye Care Professionals from the United States, United Kingdom, Japan, South Korea, China, France, and Germany conducted 10/2022 to 11/2022.
‡Source Euromonitor International Limited; Eyewear 2023 edition; value sales at rsp, all retail channels, 2021 data; “Acuvue family of brands” represents aggregated sales of the following brands: 1-day Acuvue, Acuvue Oasys, Acuvue Advance, Acuvue, and Acuvue2.
±Source Euromonitor International Limited; based on research conducted in Sept-Nov 2022; "world" and "globally" represent markets accounting for 78% of total daily disposable contact lenses in 2021 (retail sales).
#Helps protect against transmission of harmful UV radiation to the cornea and into the eye.
WARNING: UV-absorbing contact lenses are NOT substitutes for protective UV-absorbing eyewear such as UV-absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. You should continue to use UV-absorbing eyewear as directed. NOTE: Long-term exposure to UV radiation is one of the risk factors associated with cataracts. Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of outdoor activities). UV-blocking contact lenses help provide protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-blocking contact lenses reduces the risk of developing cataracts or other eye disorders. Consult your eye care practitioner for more information.
+Clinical trial results posted on ClinicalTrials.gov, a website maintained by the NIH, were reviewed as of April 30, 2023. The 46 clinical trials evaluated subjective comfort as a primary or secondary endpoint for the ACUVUE® OASYS Brand family (including daily disposable families), the 1-DAY ACUVUE® MOIST Brand family (within the category of hydrogel daily disposable), and the ACUVUE® VITA® Brand family, vs. competitors’ products.
*MyACUVUE™ membership privileges are exclusively available at participating ACUVUE® Authorised Practitioners only. Terms & conditions apply.